---
title: "SciSparc (SPRC) news: delisting, going concern and offering"
url: "https://aibio.space/companies/scisparc/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "SPRC delisting, going concern and offering news: SciSparc gets conditional Nasdaq compliance letter on stockholders' equity. SciSparc Ltd."
---

SPRC SciSparc Ltd. NASDAQ · Israel

# SciSparc (SPRC) news SPRC delisting, going concern and offering news

Listings · 2026-09-30

## [SciSparc reports $4,436 thousand in cash and $6,051 thousand loss for first half](https://aibio.space/news/scisparc-reports-4-436-thousand-cash-6-051-thousand-loss-first-half/)

SciSparc reported $4,436 thousand of cash and a $6,051 thousand net loss for the six months to June 30, 2026. Its own going concern note says these factors raise substantial doubt about its ability to continue as a going concern.

## Latest SciSparc news

1. 2026-08-18 Financings [SciSparc unit NeuroThera Labs completes C$5.4 million private placements](https://aibio.space/news/scisparc-unit-neurothera-labs-completes-c-5-4-million-private/) SciSparc put in C$2.7 million, half the total, and says it will hold approximately 44.6% of NeuroThera afterward. NeuroThera plans to use the money for general working capital.
2. 2026-05-11 Listings [SciSparc gets conditional Nasdaq compliance letter on stockholders' equity](https://aibio.space/news/scisparc-gets-conditional-nasdaq-compliance-letter-stockholders-equity/) Nasdaq staff said on May 7, 2026 that SciSparc now meets the $2,500,000 stockholders' equity standard, but the letter is conditional. Delisting is possible if the company's next periodic report does not show compliance.
3. 2026-03-12 Mergers [SciSparc unit NeuroThera Labs to buy 54.01% of CliniQuantum for shares](https://aibio.space/news/scisparc-unit-neurothera-labs-buy-54-01-percent-cliniquantum-shares/) NeuroThera would issue 56,600,000 of its own shares, valued at approximately $9,459,954.20, plus up to $2,500,000 in earn-out payments. The release does not say what the issuance would do to SciSparc's approximately 75% stake in NeuroThera.

## SciSparc at a glance

- **Ticker**: SPRC

- **Listing**: NASDAQ

- **Country**: Israel

### Related companies

- [EPITOMEE MEDICAL LTD](https://aibio.space/companies/epitomee-medical/) TASE: EPIT
- [Rekah Pharmaceutical Industry](https://aibio.space/companies/rekah-pharmaceutical-industry/) TASE: REKA
- [Nasus Pharma](https://aibio.space/companies/nasus-pharma/) AMEX: NSRX
- [BioLineRX](https://aibio.space/companies/biolinerx/) TASE: BLRX
- [Redhill Biopharma](https://aibio.space/companies/redhill-biopharma/) NASDAQ: RDHL
- [Sol-Gel Technologies](https://aibio.space/companies/sol-gel-technologies/) NASDAQ: SLGL
- [Can-Fite BioPharma](https://aibio.space/companies/can-fite-biopharma/) TASE: CANF
- [NeuroSense Therapeutics](https://aibio.space/companies/neurosense-therapeutics/) NASDAQ: NRSN

### Also on NASDAQ

- [Quanterix](https://aibio.space/companies/quanterix/) QTRX
- [Kamada](https://aibio.space/companies/kamada/) KMDA
- [MAXCYTE, INC.](https://aibio.space/companies/maxcyte/) MXCT
- [Immunocore Holdings](https://aibio.space/companies/immunocore/) IMCR
- [Lucid Diagnostics](https://aibio.space/companies/lucid-diagnostics/) LUCD
- [InMed Pharmaceuticals](https://aibio.space/companies/inmed-pharmaceuticals/) INM

## SciSparc annual financials

| Line | FY2020 | FY2019 |
|---|---|---|
| Net income (loss) | [-$3.5 million](https://www.sec.gov/Archives/edgar/data/1611746/000121390021018407/) | [-$4.7 million](https://www.sec.gov/Archives/edgar/data/1611746/000121390021018407/) |

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about SciSparc

Was SciSparc delisted?

Our latest story on this, dated May 11, 2026: "SciSparc gets conditional Nasdaq compliance letter on stockholders' equity". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/scisparc-gets-conditional-nasdaq-compliance-letter-stockholders-equity/).

Has SciSparc issued a going-concern warning?

Our latest story on this, dated Sep 30, 2026: "SciSparc reports $4,436 thousand in cash and $6,051 thousand loss for first half". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/scisparc-reports-4-436-thousand-cash-6-051-thousand-loss-first-half/).

Has SciSparc raised money recently?

Our latest story on this, dated Aug 18, 2026: "SciSparc unit NeuroThera Labs completes C$5.4 million private placements". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/scisparc-unit-neurothera-labs-completes-c-5-4-million-private/).

What is the ticker symbol of SciSparc?

SciSparc Ltd. trades under the ticker SPRC on NASDAQ.

Where is SciSparc listed?

SciSparc Ltd. is listed on NASDAQ.

What is the SEC CIK of SciSparc?

The SEC Central Index Key (CIK) for SciSparc Ltd. is 1611746. Its filings are on SEC EDGAR.

How many shares does SciSparc have outstanding?

365,444 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-04-29.

Which country or territory is SciSparc listed under?

Our directory records SciSparc Ltd. under Israel.

What does SciSparc do?

Our directory classifies SciSparc Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of SciSparc?

The ISIN recorded for SciSparc Ltd. is IL0010951403.

Does aibio.space cover SciSparc?

aibio.space lists SciSparc Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is SciSparc incorporated?

SEC records list its state or country of incorporation as L3.

Is SciSparc profitable?

SciSparc Ltd. reported a net loss of $3.5 million for the fiscal year ended Dec 31, 2020, per its annual report to the SEC.

What is the latest SciSparc (SPRC) stock news?

Our latest story on SciSparc, dated Sep 30, 2026: "SciSparc reports $4,436 thousand in cash and $6,051 thousand loss for first half". SciSparc reported $4,436 thousand of cash and a $6,051 thousand net loss for the six months to June 30, 2026. Its own going concern note says these factors raise substantial doubt about its ability to continue as a going concern. [Source](https://aibio.space/news/scisparc-reports-4-436-thousand-cash-6-051-thousand-loss-first-half/).

How long will SciSparc's cash last?

From our story of Sep 30, 2026: Its own going concern note says these factors raise substantial doubt about its ability to continue as a going concern. [Source](https://aibio.space/news/scisparc-reports-4-436-thousand-cash-6-051-thousand-loss-first-half/).

## Investor discussion: SciSparc

Members talk about SciSparc (SPRC). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at SciSparc, newest first. Each line links the filing it comes from.

1. 2026-09-30 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611746/000121390026105319/ea030686801ex99-1.htm)
2. 2026-08-18 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611746/000121390026091213/ea030256801ex99-1.htm)
3. 2026-05-11 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611746/000121390026054184/ea0290034-6k_scisparc.htm)
4. 2026-03-12 Mergers Reported a merger or acquisition agreement. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611746/000121390026027018/ea028148301ex99-1.htm)
5. 2026-03-02 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611746/000121390026022005/f6k0302202601ex99-1.htm)
6. 2026-02-12 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611746/000121390026015553/ea0276790-6k_scisparc.htm)
7. 2026-01-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611746/000121390026003395/ea027261701ex99-1_scisparc.htm)
8. 2025-11-18 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611746/000121390025112079/ea026308401ex99-1_scisparc.htm)
9. 2025-09-16 Mergers Reported a merger or acquisition agreement. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611746/000121390025088197/ea0257579-6k_scisparc.htm)
10. 2025-07-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611746/000121390025066350/ea024982702ex99-1_scisparc.htm)
11. 2025-07-22 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611746/000121390025066626/ea024982801ex99-1_scisparc.htm)
12. 2025-06-24 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611746/000121390025057295/ea024677302ex99-1_scisparc.htm)
13. 2025-05-21 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611746/000121390025046434/ea024305301ex99-1_scisparc.htm)
14. 2025-04-01 Mergers Reported a merger or acquisition agreement. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611746/000121390025026654/ea0236312-6k_scisparc.htm)
15. 2025-01-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611746/000121390025003825/ea022776402ex99-1_scisparc.htm)
16. 2024-11-27 Mergers Reported a merger or acquisition agreement. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611746/000121390024103540/ea0222976-6k_scisparc.htm)
17. 2024-11-04 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611746/000121390024094095/ea021715401ex99-1_scisparc.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SPRC on TradingView](https://www.tradingview.com/symbols/NASDAQ-SPRC/).

## SEC filings and registration

- **SEC name**: SciSparc Ltd.

- **CIK**: 1611746

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: SPRC (Nasdaq)

- **State or country of incorporation**: L3

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer

- **Business address**: 20 RAUL WALLENBERG STREET, TOWER A, TEL AVIV, Israel, 6971916

- **Phone**: 972-3-6103100

- **Shares outstanding**: 365,444 as of 2025-12-31 (20-F filed 2026-04-29)

- **Former names**: SciSparc Ltd./ADR; Therapix Biosciences Ltd.

### Recent filings (8-K and 6-K are the company's own announcements)

- [6-K](https://www.sec.gov/Archives/edgar/data/1611746/000121390026109727/ea0308752-6k_scisparc.htm) filed 2026-10-15
- [6-K](https://www.sec.gov/Archives/edgar/data/1611746/000121390026109675/ea0308722-6k_scisparc.htm) filed 2026-10-15
- [6-K](https://www.sec.gov/Archives/edgar/data/1611746/000121390026107436/ea0307937-6k_scisparc.htm) filed 2026-10-07
- [6-K](https://www.sec.gov/Archives/edgar/data/1611746/000121390026105319/ea0306868-6k_scisparc.htm) filed 2026-09-30
- [6-K](https://www.sec.gov/Archives/edgar/data/1611746/000121390026102810/ea0306377-6k_scisparc.htm) filed 2026-09-24
- [6-K](https://www.sec.gov/Archives/edgar/data/1611746/000121390026096690/ea0304384-6k_scisparc.htm) filed 2026-09-02
- [6-K](https://www.sec.gov/Archives/edgar/data/1611746/000121390026093941/ea0303449-6k_scisparc.htm) filed 2026-08-26
- [6-K](https://www.sec.gov/Archives/edgar/data/1611746/000121390026092838/ea0303150-6k_scisparc.htm) filed 2026-08-24

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001611746), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

SciSparc Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SPRC, recorded under Israel. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: SciSparc Ltd.

- **Ticker**: SPRC

- **Listing**: NASDAQ

- **Country or territory**: Israel

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: IL0010951403

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SPRC/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/scisparc/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "SciSparc (SPRC) news: delisting, going concern and offering", 2026-10-31, https://aibio.space/companies/scisparc/